Use of mucolytics and inhaled antibiotics in the NICU

Area of Science:

• Neonatal intensive care
• Respiratory medicine
• Pharmacology

Background:

• Airway secretion clearance and respiratory tract infection (RTI) treatment are critical in the neonatal intensive care unit (NICU).
• Current treatments like systemic antibiotics for RTIs have adverse effects, and mucolytics are less studied in neonates.
• Physiologic differences in infants necessitate specific research, distinct from adult and older pediatric data.

Purpose of the Study:

• To address the need for evidence-based use of inhaled mucolytics and antibiotics in the NICU.
• To evaluate the safety, efficacy, and optimal dosing of these inhaled therapies in neonates.
• To bridge the gap in knowledge regarding respiratory care for premature and term infants.

Main Methods:

• Review of existing literature on inhaled mucolytics and antibiotics in neonatal populations.
• Analysis of case series and small studies describing their use in the NICU.
• Identification of knowledge gaps and areas for future clinical trials.

Main Results:

• Limited data exists on inhaled mucolytics and antibiotics in the NICU, with small case series providing preliminary insights.
• Systemic antibiotics for RTIs are common but linked to adverse effects.
• Inhaled antibiotics show potential for targeted delivery and reduced systemic toxicity.

Conclusions:

• There is an urgent need to establish the safety and efficacy of inhaled mucolytics and antibiotics in neonates.
• Further research is required to determine optimal dosing strategies for varying gestational and post-natal ages.
• Developing evidence-based guidelines for inhaled respiratory therapies in the NICU is crucial for improving infant outcomes.